Knight Therapeutics and Triumvira Immunologics Triumphantly Announce Secured Bridge Loan & License Agreement
MONTREAL and AUSTIN, Texas and HAMILTON, Ontario, Feb. 20, 2019 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative...Read More >>